The Colorado Association of School Nurses (CASN) successfully updated the undesignated stock epinephrine law to include alternate forms of epinephrine in SB25-278.
After the FDA approved Neffy 2 mg epinephrine nasal spray for emergency treatment of allergic reactions in children over 66 lbs on August 9, 2024. Subsequently, on March 5, 2025, the FDA approved Neffy 1mg for pediatric patients weighing between 33 and 66 pounds (15-30 kg). Unfortunately, the stock undesignated epinephrine law in Colorado only supported the use of auto-injectors. Colorado School Nurses requested intranasal and any additional forms of FDA-approved epinephrine included in the Undesignated Epinephrine Law.
Acknowledging our members' requests, the CASN executive board contacted their paid lobbyist in February 2025 for assistance in updating the law to support all forms of FDA-approved epinephrine.
In Colorado, the legislative session begins in January. By February, proposed bills were assigned, and the session was closed to the acceptance of any new bills. Fortunately, CASN already had several positive working relationships with members of the Senate and the House; and with negotiating and collaboration, a Senator and House Representative picked up our bill as a sponsor, and SB25-278 was added to the 2025 legislative session.
CASN was required to complete additional legwork. The co-chair of the advocacy committee contacted Neffy and the state pharmacy association, and both agreed that the bill would need to be updated in order for Neffy to be supplied as a stock, undesignated epinephrine in the schools. CASN nurses testified in the Committee and the House. With minimal change in the bill’s wording, SB25-278 passed unanimously through committee, appropriations, and both chambers, and was signed by the governor on May 30, 2025.
|